Immune cell therapeutics - Adicet Bio/Regeneron

Drug Profile

Immune cell therapeutics - Adicet Bio/Regeneron

Latest Information Update: 06 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Adicet Bio; Regeneron Pharmaceuticals
  • Developer Regeneron Pharmaceuticals
  • Class Antineoplastics; CAR-T cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 02 Aug 2016 Preclinical trials in Haematological malignancies in USA (Parenteral)
  • 02 Aug 2016 Preclinical trials in Solid tumours in USA (Parenteral)
  • 02 Aug 2016 Regeneron Pharmaceuticals and Adicet Bio enter into a collaboration and licensing agreement to develop immune cell therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top